Bioanalysis Zone

Practical considerations for protein bioanalysis (Waters Corporation)


Proteins and peptides represent a growing class of therapeutics due to their target specificity, lower toxicity, and higher potency. Historically, monoclonal antibodies have been quantified using (LBAs). Recently there has been a trend toward increased analysis using LC-MS, which offers the benefits of multiplexing, improved specificity, broader linear dynamic range, and faster method development times. In addition, LC-MS avoids common LBA shortcomings such as cross reactivity and anti-drug antibody effects in the assay. However, quantification of proteins by LC-MS is not without its challenges. There is no single standardized workflow and the multitude of workflow options can make it difficult to know where to obtain optimal results.

Click here to view poster


Comments are closed.